Active human full-length CDKL5 produced in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125.

Antarctic bacterium Bicistronic design In cellulo kinase assay Intrinsically disordered protein (IDP) Pseudoalteromonas haloplanktis TAC125 Psychrophilic gene expression system Recombinant protein aggregation Recombinant protein condensation Tricistronic design

Journal

Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812

Informations de publication

Date de publication:
14 Oct 2022
Historique:
received: 04 07 2022
accepted: 24 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 19 10 2022
Statut: epublish

Résumé

A significant fraction of the human proteome is still inaccessible to in vitro studies since the recombinant production of several proteins failed in conventional cell factories. Eukaryotic protein kinases are difficult-to-express in heterologous hosts due to folding issues both related to their catalytic and regulatory domains. Human CDKL5 belongs to this category. It is a serine/threonine protein kinase whose mutations are involved in CDKL5 Deficiency Disorder (CDD), a severe neurodevelopmental pathology still lacking a therapeutic intervention. The lack of successful CDKL5 manufacture hampered the exploitation of the otherwise highly promising enzyme replacement therapy. As almost two-thirds of the enzyme sequence is predicted to be intrinsically disordered, the recombinant product is either subjected to a massive proteolytic attack by host-encoded proteases or tends to form aggregates. Therefore, the use of an unconventional expression system can constitute a valid alternative to solve these issues. Using a multiparametric approach we managed to optimize the transcription of the CDKL5 gene and the synthesis of the recombinant protein in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125 applying a bicistronic expression strategy, whose generalization for recombinant expression in the cold has been here confirmed with the use of a fluorescent reporter. The recombinant protein largely accumulated as a full-length product in the soluble cell lysate. We also demonstrated for the first time that full-length CDKL5 produced in Antarctic bacteria is catalytically active by using two independent assays, making feasible its recovery in native conditions from bacterial lysates as an active product, a result unmet in other bacteria so far. Finally, the setup of an in cellulo kinase assay allowed us to measure the impact of several CDD missense mutations on the kinase activity, providing new information towards a better understanding of CDD pathophysiology. Collectively, our data indicate that P. haloplanktis TAC125 can be a valuable platform for both the preparation of soluble active human CDKL5 and the study of structural-functional relationships in wild type and mutant CDKL5 forms. Furthermore, this paper further confirms the more general potentialities of exploitation of Antarctic bacteria to produce "intractable" proteins, especially those containing large intrinsically disordered regions.

Sections du résumé

BACKGROUND BACKGROUND
A significant fraction of the human proteome is still inaccessible to in vitro studies since the recombinant production of several proteins failed in conventional cell factories. Eukaryotic protein kinases are difficult-to-express in heterologous hosts due to folding issues both related to their catalytic and regulatory domains. Human CDKL5 belongs to this category. It is a serine/threonine protein kinase whose mutations are involved in CDKL5 Deficiency Disorder (CDD), a severe neurodevelopmental pathology still lacking a therapeutic intervention. The lack of successful CDKL5 manufacture hampered the exploitation of the otherwise highly promising enzyme replacement therapy. As almost two-thirds of the enzyme sequence is predicted to be intrinsically disordered, the recombinant product is either subjected to a massive proteolytic attack by host-encoded proteases or tends to form aggregates. Therefore, the use of an unconventional expression system can constitute a valid alternative to solve these issues.
RESULTS RESULTS
Using a multiparametric approach we managed to optimize the transcription of the CDKL5 gene and the synthesis of the recombinant protein in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125 applying a bicistronic expression strategy, whose generalization for recombinant expression in the cold has been here confirmed with the use of a fluorescent reporter. The recombinant protein largely accumulated as a full-length product in the soluble cell lysate. We also demonstrated for the first time that full-length CDKL5 produced in Antarctic bacteria is catalytically active by using two independent assays, making feasible its recovery in native conditions from bacterial lysates as an active product, a result unmet in other bacteria so far. Finally, the setup of an in cellulo kinase assay allowed us to measure the impact of several CDD missense mutations on the kinase activity, providing new information towards a better understanding of CDD pathophysiology.
CONCLUSIONS CONCLUSIONS
Collectively, our data indicate that P. haloplanktis TAC125 can be a valuable platform for both the preparation of soluble active human CDKL5 and the study of structural-functional relationships in wild type and mutant CDKL5 forms. Furthermore, this paper further confirms the more general potentialities of exploitation of Antarctic bacteria to produce "intractable" proteins, especially those containing large intrinsically disordered regions.

Identifiants

pubmed: 36242022
doi: 10.1186/s12934-022-01939-6
pii: 10.1186/s12934-022-01939-6
pmc: PMC9563788
doi:

Substances chimiques

Proteome 0
Recombinant Proteins 0
Threonine 2ZD004190S
Serine 452VLY9402
Protein Kinases EC 2.7.-
Protein Serine-Threonine Kinases EC 2.7.11.1
CDKL5 protein, human EC 2.7.11.22
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

211

Subventions

Organisme : Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
ID : CDKL5-20-101-08
Organisme : Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
ID : CDKL5-20-101-08
Organisme : Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
ID : CDKL5-20-101-08

Informations de copyright

© 2022. The Author(s).

Références

Appl Microbiol Biotechnol. 2017 Jan;101(2):725-734
pubmed: 27796433
Mol Cell Biol. 2006 Nov;26(22):8639-54
pubmed: 16954377
Hum Mol Genet. 2017 Sep 15;26(18):3520-3530
pubmed: 28641386
Anal Biochem. 2019 Feb 1;566:58-61
pubmed: 30447183
Hum Mol Genet. 2018 May 1;27(9):1572-1592
pubmed: 29474534
J Biotechnol. 2007 Jan 1;127(2):199-210
pubmed: 16959351
Methods Mol Biol. 2022;2406:219-232
pubmed: 35089560
Sci Adv. 2015 Jul;1(6):
pubmed: 26322332
Philos Trans R Soc Lond B Biol Sci. 2017 Mar 19;372(1716):
pubmed: 28138069
Neurol Genet. 2017 Dec 15;3(6):e200
pubmed: 29264392
Cell Rep. 2018 Jan 23;22(4):885-894
pubmed: 29420175
Protein Sci. 2011 Aug;20(8):1285-97
pubmed: 21574196
Pediatr Neurol. 2019 Aug;97:18-25
pubmed: 30928302
J Biol Chem. 2019 Nov 29;294(48):18046-18056
pubmed: 31604819
Hum Mutat. 2017 Aug;38(8):922-931
pubmed: 28544139
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1162-7
pubmed: 18977197
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W126-31
pubmed: 17439967
Curr Opin Struct Biol. 2011 Feb;21(1):25-31
pubmed: 21111607
EMBO J. 2018 Dec 14;37(24):
pubmed: 30266824
Elife. 2015 Feb 19;4:
pubmed: 25695637
Environ Microbiol. 2015 Mar;17(3):751-66
pubmed: 24889559
Nat Commun. 2015 Aug 19;6:8088
pubmed: 26286827
J Biotechnol. 2006 Dec 15;127(1):141-50
pubmed: 16859797
Mol Cell Biol. 2005 Jul;25(14):6047-64
pubmed: 15988018
ACS Synth Biol. 2015 Mar 20;4(3):249-57
pubmed: 24931615
Extremophiles. 2001 Aug;5(4):257-64
pubmed: 11523895
Int J Mol Sci. 2019 Nov 08;20(22):
pubmed: 31717404
PLoS One. 2016 Jun 17;11(6):e0157758
pubmed: 27315173
Biotechnol Lett. 2016 Dec;38(12):2119-2126
pubmed: 27580890
PLoS One. 2016 Feb 05;11(2):e0148634
pubmed: 26849555
Appl Microbiol Biotechnol. 2015 Jul;99(14):5863-74
pubmed: 25616525
Biochemistry. 2015 May 19;54(19):2975-87
pubmed: 25905439
Metabolites. 2021 Jul 28;11(8):
pubmed: 34436432
PLoS One. 2008;3(11):e3647
pubmed: 18985154
Mar Genomics. 2008 Sep-Dec;1(3-4):123-8
pubmed: 21798163
EMBO J. 2021 Dec 1;40(23):e108271
pubmed: 34605059
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Nat Methods. 2013 Apr;10(4):354-60
pubmed: 23474465
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34651584
Nat Commun. 2020 Apr 21;11(1):1924
pubmed: 32317630
Brain. 2020 Mar 1;143(3):811-832
pubmed: 32125365
Nat Commun. 2019 Dec 18;10(1):5774
pubmed: 31852903
Sci Rep. 2019 Nov 11;9(1):16444
pubmed: 31712730
Microorganisms. 2020 Sep 24;8(10):
pubmed: 32987756
J Biol Chem. 2006 Oct 20;281(42):32048-56
pubmed: 16935860
J Biol Chem. 1997 Apr 25;272(17):11057-62
pubmed: 9110999
EMBO J. 2018 Dec 14;37(24):
pubmed: 30266825
Hum Mol Genet. 2005 Dec 15;14(24):3775-86
pubmed: 16330482

Auteurs

Andrea Colarusso (A)

Department of Chemical Sciences, "Federico II" University of Naples, Complesso Universitario Monte S. Angelo-Via Cintia, 80126, Naples, Italy.
Istituto Nazionale Biostrutture e Biosistemi-I.N.B.B., Viale Medaglie d'Oro, 305-00136, Rome, Italy.

Concetta Lauro (C)

Department of Chemical Sciences, "Federico II" University of Naples, Complesso Universitario Monte S. Angelo-Via Cintia, 80126, Naples, Italy.
Istituto Nazionale Biostrutture e Biosistemi-I.N.B.B., Viale Medaglie d'Oro, 305-00136, Rome, Italy.

Marzia Calvanese (M)

Department of Chemical Sciences, "Federico II" University of Naples, Complesso Universitario Monte S. Angelo-Via Cintia, 80126, Naples, Italy.

Ermenegilda Parrilli (E)

Department of Chemical Sciences, "Federico II" University of Naples, Complesso Universitario Monte S. Angelo-Via Cintia, 80126, Naples, Italy.

Maria Luisa Tutino (ML)

Department of Chemical Sciences, "Federico II" University of Naples, Complesso Universitario Monte S. Angelo-Via Cintia, 80126, Naples, Italy. tutino@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH